GLP-2/Tirz vs IGF-1 LR3
GLP-2/Tirz and IGF-1 LR3 are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: GLP-2/Tirz is lipidated dual receptor agonist (gip / glp-1), 39-residue chain, while IGF-1 LR3 is recombinant 83-residue protein analogue of igf-1 — different molecular classes with different handling consequences; they call for different primary diluents (bacteriostatic water (0.9% benzyl alcohol) versus dilute acetic acid (0.1 m) or 10 mm hcl — required for initial dissolution); their leading degradation routes differ (interfacial aggregation from agitation or freezing for GLP-2/Tirz, denaturation and aggregation for IGF-1 LR3), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
GLP-2/Tirz — origin
GLP-2/Tirz is built on a GIP-based backbone rather than a GLP-1 one — an important and often-missed design detail. It was engineered from the GIP sequence and modified to acquire GLP-1 receptor activity, with a C20 fatty diacid attached via a linker for albumin binding. The term "twincretin" describes the dual incretin activity.
IGF-1 LR3 — origin
IGF-1 LR3 is an engineered analogue carrying two changes to native IGF-1: an arginine substitution at position 3 and a 13-residue N-terminal extension. The Arg3 substitution is the functional one — it drastically reduces binding to IGF binding proteins, which normally sequester the great majority of circulating IGF-1. The result is a molecule that stays free rather than bound.
GLP-2/Tirz research themes
Simultaneous GIP and GLP-1 receptor activity from a GIP-derived backbone.
Core metabolic research endpoints for the incretin class.
A well-characterised GLP-1 pathway effect studied in metabolic models.
Whether GIP agonism or antagonism is the productive direction remains an active research debate.
IGF-1 LR3 research themes
The Arg3 substitution reduces binding-protein affinity, which is the entire design rationale.
Widely used in cell-culture research as a growth-factor supplement.
Studied in muscle-biology research models.
The canonical downstream pathway examined in IGF-1 receptor research.
GLP-2/Tirz handling
- Swirl, never shake or vortex.
- Add diluent down the vial wall and give the cake time — several minutes of slow dissolution is normal, not a defect.
- Store upright and refrigerated; do not freeze once reconstituted.
IGF-1 LR3 handling
- Dissolve in dilute acetic acid or dilute HCl FIRST; do not attempt direct dissolution in water or PBS.
- Add carrier protein (e.g. 0.1% BSA) for storage of dilute solutions to prevent adsorptive loss.
- Prepare single-use aliquots — freeze–thaw denaturation is irreversible.
- Do not vortex; agitation denatures folded proteins at the air–liquid interface.
Both third-party tested
Every Popular Peptides batch of GLP-2/Tirz and IGF-1 LR3 is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
GLP-2/Tirz reference
Related comparisons
GLP-2/Tirz and IGF-1 LR3 are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.